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Vitiligo is an autoimmune disease of the skin that is characterized by patchy depigmentation (i.e., white
spots) and results from the loss of melanocytes, which are pigment-producing cells. The pathogenesis of
human vitiligo consists of an interaction between intrinsic melanocyte defects, environmental factors,
and autoimmune mechanisms that target these cells for destruction. Human clinical and translational
studies have outlined pathways that are important in human disease; however, combining human
correlative studies with mechanistic studies in representative preclinical animal models is a powerful
approach to study disease pathogenesis and develop new treatments. Because of the complex patho-
genesis of vitiligo, it is unlikely that any one single animal model will adequately reﬂect all factors
implicated in the initiation, progression, and maintenance of the disease. Therefore, vitiligo is best
modeled by multiple systemsdeach with its strengths and weaknessesdthat allow insight into speciﬁc
components of vitiligo pathogenesis. In this paper, we describe some of the available animal models that
have been developed to study vitiligo.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Human vitiligo pathogenesis
Vitiligo affects 0.5e1% of the population and is characterized by
skin depigmentation resulting from the loss of melanocytes that
produce epidermal pigment. Men and women are equally affected,
and one-half of patients develop vitiligo before the age of 20 years.
Patients and their family members are at higher risk for other
autoimmune diseases such as thyroiditis, type 1 diabetes,
pernicious anemia, Addison's disease, and alopecia areata. Depig-
mentation frequently affects the face, hands, feet, and genitals,
although any part of the skin may be involved. The affected skin
lacks epidermal melanocytes, whereas hair follicles within thes of interest.
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cal Association. Published by Elsevlesional skin are often spared, likely because of the immune
privilege of the hair follicle. Successful treatment results in repig-
mentation of the skin that begins around the hair follicles, and
presumably originates from melanocyte stem cell reservoirs that
are protected within the follicle.1e3 Patients with vitiligo have a
three-fold decreased risk of developing melanoma, and patients
with melanoma who spontaneously develop vitiligo have a better
prognosis because they sometimes clear their tumor.4 New mela-
noma treatments that activate antitumor immunity have had
impressive success in the clinic, but the treatments also induce
vitiligo.5,6 These observations strongly suggest that melanocyte-
speciﬁc immune responses are shared between vitiligo and
melanoma immunity. The pathogenesis of vitiligo involves multiple
components such as intrinsic melanocyte defects, environmental
factors, autoimmunity, and genetic factors that inﬂuence each of
these components.3,7e9
Melanocytes from uninvolved vitiligo skin grow less efﬁciently
than melanocytes from healthy patients and they exhibit structural
defects, which indicate intrinsic abnormalities.10,11 They also die
more readily in response to exogenous oxidative stressors,
compared to normal melanocytes.12,13 They contain elevated levels
of reactive oxygen species14,15 and greater endoplasmic reticulum
stress.10 These abnormalities may also be induced after exposing
the skin to chemical phenols such as 4-tert-butylphenol and
monobenzyl ether of hydroquinone (i.e., monobenzone), whichier Taiwan LLC. All rights reserved.
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induced stress results in proinﬂammatory signals that activate
autoimmunity and are most likely responsible for inducing viti-
ligo.16 Thus intrinsic melanocyte stress has an important role in
vitiligo pathogenesis, and chemical tyrosine analogs such as mon-
obenzone appear to be environmental factors that promote the
disease.
Innate immunity is apparently activated in the affected and
unaffected skin of patients with vitiligo, and innate responses may
be initiated by the proinﬂammatory signals produced by stressed
melanocytes.7 For example, natural killer (NK) cell inﬁltration is
elevated in the affected and unaffected skin in vitiligo patients,
compared to controls.18 Furthermore, inﬂammatory dendritic cells
have been implicated in lesions and in the peripheral blood of
vitiligo patients. These cells may be induced by the release of
HSP70i from melanocytes, which occurs during chemical-induced
stress.19,20 These observations support a role for innate immunity
in vitiligo and suggest that innate immune cells may respond to
melanocyte stress.
Elevated levels of melanocyte-speciﬁc antibodies have been
reported in the serum of vitiligo patients, including those that
target VIT40, tyrosinase-related protein 1 (TRP1), tyrosinase-
related protein 2 (TRP2), and gp100.21 These antibodies kill
cultured human melanocytes in vitro.22 Puriﬁed immunoglobulin G
from the sera of patients with vitiligo destroys melanocytes in
human skin grafted onto nude mice.23 However, autoantibodies in
vitiligo patients are not correlated with disease severity.24 Auto-
antibodies exist systemically, but distinct patches of skin are
affected. Therefore, the contribution of autoantibodies to vitiligo
pathogenesis is unclear.
T cell-driven immune responses are strongly implicated in dis-
ease pathogenesis. CD8þ T cells inﬁltrate the epidermis of vitiligo
patients. They express high levels of perforin and granzyme, which
reﬂects their cytotoxic phenotype.25,26 CD8þ T cells that recognize
melanocyte antigens such as MART1, gp100, and tyrosinase exist in
higher numbers in the blood and perilesional skin from vitiligo
patients, compared to healthy donors.27e29 The frequency of
autoreactive CD8þ T cells is correlated with disease severity.27 In
fact, CD8þ T cells (but not other T cell populations) isolated directly
from lesional vitiligo skin are capable of migrating into the
epidermis of normal skin from the same donor and inducing me-
lanocyte apoptosis,30 which suggests that CD8þ T cells are neces-
sary and sufﬁcient for melanocyte destruction in human vitiligo.
Interferon (IFN)-g and IFN-g-dependent chemokines are expressed
in lesional skin in vitiligo.29e31 This ﬁnding is consistent with a
CD8þ T cell-driven response.
It is likely that an interplay between melanocyte stress and
autoimmunity initiates vitiligo and sustains melanocyte destruction,
and studies to identify genes associated with vitiligo support this
concept. Associations include genes that are important in melano-
cyte function (e.g., tyrosinase, OCA2, andMC1R), in the cellular stress
response (e.g., XBP1), in innate immunity (e.g., NLRP1, IFIH1, and
TICAM1), and in adaptive immunity (e.g., GZMB, HLA-A, FoxP3, and
CD80). Some risk alleles for vitiligo are also protective alleles for
melanoma, which supports the clinical observation that vitiligo im-
munity effectively targets melanoma.32 Functional studies to deter-
mine a role for these genes in vitiligo pathogenesis are now needed,
and studies in humans and preclinical animal models should be
useful. The connections between intrinsicmelanocyte abnormalities,
innate immune activation, and adaptive immunity are unclear. The
connections may also be difﬁcult to deﬁne using only human in-
dividuals and their tissues. Therefore, animal models provide an
excellent opportunity to further dissect the pathogenesis of vitiligo.
However, no model reﬂects every aspect of the disease. For
example, it is important to consider the differences betweenmelanocytes in humans and those of other species, and to consider
whether these differences impact their utility as models for human
disease. One key difference is the distribution of melanocytes in the
skin. Human melanocytes reside in the hair follicles and in the
epidermis of hair-bearing skin. However, mouse melanocytes pri-
marily reside in the follicles and are absent from the hair-bearing
epidermis. They are present in low numbers in the epidermis at
sites lacking fur such as the ear, nose, tail, and paw.33,34 Evenwithin
human skin, there are differences between melanocytes in the
epidermis and melanocytes in the hair follicle.34 Follicular mela-
nocytes only perform melanogenesis during the anagen phase of
hair growth, whereas epidermal melanocytes continuously pro-
duce melanin. Compared to epidermal melanocytes, active follic-
ular melanocytes are larger than epidermal melanocytes, have a
more extensive Golgi apparatus and rough endoplasmic reticulum,
and have an increased sensitivity to aging.34 Because of these dis-
tinctions between human melanocytes at different anatomical lo-
cations, melanocytes are likely to vary in form and function
between species. Unlike humans, mice are generally nocturnal, and
therefore mouse melanocytes may have evolved to fulﬁll different
tasks. Functional differences between murine melanocytes and
human melanocytes include the fact that tyrosine related protein 1
(TRP1) acts on a different substrate in mouse melanocytes than in
human melanocytes during the biochemical conversion of tyrosine
to melanin,35 and murine melanocytes transfer melanin into the
medulla of growing hairs. By contrast, human melanin is trans-
ferred to the cortex.34 Melanocytes in murine follicles and human
epidermal melanocytes could have relevant biological differences
that may be overlooked in an animal model of vitiligo. This caveat
should always be considered when interpreting results.
Spontaneous models and induced models of vitiligo have been
identiﬁed and developed, and each has distinct advantages and
disadvantages. Induced models of vitiligo enable investigation of
immune events during disease progression and offer a consistent,
synchronized presentation of disease. However, depigmentation
results from an intentional breaking of immune tolerance through
the adoptive transfer of melanocyte-speciﬁc T cells, or the admin-
istration of antigen and immune adjuvants, or both. Therefore
induced models may not exhibit early initiating events of vitiligo.
Spontaneous models develop in a more physiologic way, which
provides an opportunity to study the initiating events in the disease
and how these events translate to autoimmunity. However, the
time and cost required to follow a colony of animals that develop a
low incidence of disease can be time-consuming and costly.
Animal models of vitiligo that develop spontaneously
Several animal species reportedly spontaneously develop vitiligo.
Sinclair swine depigmentation and cellular and humoral immunity
against melanocytes have been reported in association with dis-
ease. Theywere bred to exhibit a high incidence of melanomad54%
of these animals are bornwith melanoma and 85% of them develop
melanomaswithin the 1st year of lifedbut in 90% of animals tumors
spontaneously resolve and are accompanied by local depigmenta-
tion of the skin and hair. Between the 4th week and 16th week of life,
depigmentation may then spread from the local site and generally
involve the skin, hair, and melanocytes in the iris of the eye36,37
(Figure 1). Peripheral blood leukocytes from affected individuals
kill melanocytes in vitro, and antibodies to vitiligo antigens are
present in their serum.38 These events are consistent with mela-
noma regression, followed by depigmentation in humans, and
therefore Sinclair swine may provide an opportunity to study
crosstalk between melanoma and vitiligo.
Breeds of horses with the Gray allele (which encodes STX17 and
is involved in vesicle transport) such as Arabians, Andalusians, and
Figure 1 Vitiligo in Sinclair swine. (A, B) Sinclair swine exhibit a high incidence of melanoma. In 90% of animals, tumors spontaneously resolve and are accompanied by local
depigmentation of the skin and hair (arrow). (The pig is a 12-month-old female.) In some animals, depigmentation can become more widespread with age and involve (C) the skin
and hair and (D) the eye. Disease severity is somewhat unpredictable, but may be correlated with tumor burden. (The pig is a 23-month-old boar.) Note: Ino Curik: University of
Zagreb, Svetosimunska Zagreb, Croatia; Thomas Druml: University of Veterinary Medicine Vienna, Vienna, Austria; Monika Seltenhammer: Medical University of Vienna, Vienna,
Austria; Johan Solkner: University of Natural Resources and Life Science Vienna, Vienna, Austria.
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on the face, perianal, perioral, and perigenital areas.39 Vitiligo in
these horse breeds is also associated with an increased incidence of
melanoma, similar to what is seen in Sinclair swine, and early
graying of the hair that may or may not be related to vitiligo
(Figure 2).37,40,41 Little is known about the mechanism of vitiligo in
horses, but sera from affected horses contain antibodies against
surface melanocyte antigens.42 Therefore, horses may be helpful
models to study antibody formation in vitiligo, particularly because
they provide large quantities of serum for antibody puriﬁcation.
Certain dog breeds are genetically predisposed to develop viti-
ligo such as Rottweilers, German Shepherds, Old English Sheep-
dogs, Doberman Pinschers, Dachshunds, and German Shorthaired
Pointers. In general, affected animals have serum autoantibodies
against melanocyte antigens that are not present in healthy ani-
mals.42,43 Dog breeds are genetically homogeneous, enabling
powerful genome-wide association studies that require fewer in-
dividuals for statistical power than humans.44 Human genome-
wide association studies are preferred; however, identifying addi-
tional genes at some point becomes cost-prohibitive because of the
small contributions of individual genes to disease pathogenesis and
because of the genetic heterogeneity in humans. Therefore, dogs
represent a physiologic onset and time course of the disease, and
may provide an excellent model in which to further investigate
genetic contributions to the disease.
Vitiligo in the Smyth line (SL) chicken exhibits many of the
pathogenic characteristics of human vitiligo, which provides an
opportunity to investigate the interplay between genetic compo-
nents, melanocyte defects, stress, and humoral and cellular im-
mune responses that are potentially involved in the onset and
pathogenesis of the disease. Smyth line vitiligo (SLV) ischaracterized by depigmentation of the feathers (Figure 3). Up to
70e95% of hatchlings develop depigmentation when vaccinated to
prevent lymphoma, yet without vaccination the incidence is
lower.45 Viral infections have been proposed as environmental
triggers of autoimmunity in vitiligo, but deﬁnitive evidence of this
is lacking. The SLV model nevertheless exhibits a much higher
incidence of vitiligo, compared to humans (with an incidence of
0.5e1%).
Patchy depigmentation in SLV presents during early adulthood
at 6e14 weeks of age and varies in severity. Smith line chickens are
also susceptible to uveitis and other autoimmune diseases associ-
ated with human vitiligo such as hypothyroidism and feather loss
that is similar to alopecia areata. Melanocyte abnormalities and
cellular stress are both implicated in SLV. Reactive oxygen species
are increased in SL feathers and in other organs, and melanocytes
have numerous notable morphological abnormalities. As in
humans, these defects are insufﬁcient for disease, but require im-
mune responses.45,46
Similar to human vitiligo, CD8þ T cells inﬁltrate the feathers of
SL chickens with active disease,47e49 and IFN-g, and IFN-g-induced
genes are expressed in the affected feathers.47 Melanocyte auto-
antibodies have been isolated from SL chickens with vitiligo.50
Bursectomy decreases the incidence of disease,51 which suggests
that B cells, and possibly autoantibodies, are involved in melano-
cyte destruction. Because of the sequencing of the chicken
genome52 and the availability of parental control lines, SLV may be
a good model for genetic studies. The Brown line chicken is the
parental line for SLV and has a low incidence of spontaneous vitiligo
that increases after treatment with 5-azacytidine, an inhibitor of
DNA methylation. The Light-brown Leghorn line shares an major
histocompatibility complex (MHC) haplotype with the Smith line,
Figure 2 Vitiligo due to the Gray allele in Lipizzaner horses. Horses with the Gray mutation in STX17 develop premature hair graying, an increased incidence of melanomas, and
vitiligo-like depigmentation of the skin. (A) A group of young horses, which were born dark but exhibit variable amounts of graying, depending on whether they are homozygous or
heterozygous for the Gray allele. (B) The horse in the foreground was originally born dark, as was the horse in the background, but now exhibits hair speckling and vitiligo-like skin
depigmentation around the eye. (C) Gradual patchy graying of the hair. (D) Patchy vitiligo of the skin around the nose, cheek, and eye in an aging horse. (E) Perianal patchy
depigmentation of the skin, associated with a nodule of melanoma on the underside of the tail (arrow). Note: Photos courtesy of Drs. Ino Curik: University of Zagreb, Svetosimunska
Zagreb, Croatia, Thomas Druml: University of Veterinary Medicine Vienna, Vienna, Austria, Monika Seltenhammer: Medical University of Vienna, Vienna, Austria, and Johann
S€olkner: University of Natural Resources and Life Science Vienna, Vienna, Austria.
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and is therefore a vitiligo-resistant line.45
The Jackson Laboratory (Bar Harbor, ME, USA) discovered the
mivit/mivit mouse strain. It is the ﬁrst inbred strain with sponta-
neous depigmentation that is inherited in a recessive manner.53
Depigmentation in this strain occurs because of the loss of mela-
nocyte function and occurs in the absence of a functional immune
system. A point mutation in the microphthalmia-associated tran-
scription factor (MITF) gene is responsible for the phenotype.54 The
MITF gene directly inﬂuences melanocyte development and regu-
lates genes important for melanin production such as tyrosinase.55
Because of the monogenic nature and lack of autoimmunity in the
mivit/mivit mouse,53,54 this strain does not appear to accurately
model human vitiligo pathogenesis. The identical mutation in
humans, a single arginine deletion in the basic domain ofMITF does
not result in vitiligo, but results in partial albinism and deafness.56
To date, MITF mutations do not appear to be genetically linked to
human vitiligo.57 Because of these clear differences with human
vitiligo, this strain is not widely used as a model to study vitiligo
pathogenesis.
The spontaneous development of vitiligo in animal models
provides an opportunity to study causative factors that initiate
disease such as genetic inﬂuences and potential environmental
triggers. However, the typically low incidence of the disease, the
limited resources available for mechanistic studies, and the cost of
care for these animals can be difﬁcult. Induced mouse models of
vitiligo are limited in providing the ability to investigate genetic
inﬂuences and other initiating events in vitiligo; however, they
provide an opportunity to investigate disease mechanisms during
the progression of vitiligo in a synchronized and predictable system
with many tools available for mechanistic studies. Theaforementioned Brown line chicken develops vitiligo after the
administration of 5-azacytidine, whereas the remaining induced
models of vitiligo are conducted in mice.
Induced mouse models of vitiligo
Several methods have been developed to induce depigmentation in
mice to model vitiligo. Many of these approaches initially induced
therapeutic immune responses against melanoma, and result in
depigmentation as an unanticipated side effect. These approaches
include chemically inducing melanocyte stress, immunizing mice
with melanocyte antigens plus immune adjuvants to activate
endogenous immune cells, or genetically altering mice to increase
the frequency of melanocyte-reactive T cells. Genetically altered
mice express a single T cell receptor (TCR) in their T cells that is
speciﬁc for a particular melanocyte antigen, and therefore all of
their T cells only recognize that one antigen. To more closely model
human vitiligo in which T cells speciﬁc for a particular melanocyte
antigen are limited to a small percentage of the total T cell popu-
lation, some models use the adoptive transfer of a small number of
TCR transgenic T cells to a host with a normal immune system. Each
approach has advantages and disadvantages, which we will discuss
in the following section.
Induced vitiligo through melanocyte stress
As discussed previously, monobenzone is a clinically relevant
chemical analog of tyrosine that induces cellular stress in mela-
nocytes, induces proinﬂammatory signals, and exacerbates depig-
mentation in vitiligo patients.16 Zhu et al58 applied monobenzone
to the shaved abdomens of 4-week-old mice; hair depigmentation
Figure 3 Vitiligo in the Smyth line chicken. (A) Normal pigmentation in Smyth line and Brown line chicks. (B) Smyth line adults before developing vitiligo. (C) The onset of vitiligo is
evident by depigmentaion of the feathers, which occurs in varying degrees in each bird. Note: Photos courtesy of Dr. Gisela F. Erf, Division of Agriculture, University of
ArkansaseFayetteville, Fayetteville, AR, USA.
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sites such as the ear and tail. CD8þ T cells inﬁltrate the affected skin
after treatment. The same treatment in RAG-deﬁcient mice resulted
in hair depigmentation at the treatment site, but not at distant
sites.58 These ﬁndings suggest that direct toxicity of monobenzone
may be responsible for localized depigmentation at the site of
application, but an adaptive immune response is required for
depigmentation to spread to other sites. This model may help
identify the mechanisms by which monobenzone-induced stress
activates the immune response in vitiligo.Induced vitiligo through immunization
In an approach to induce melanoma immune responses, one group
constructed recombinant vaccinia viruses (rVV) that expressed a
variety of melanocyte antigens. They used these viruses to vacci-
nate C57Bl6 mice and found that infection with rVV that expressed
human TRP1 resulted in depigmentation of the hair follicles in 80%
of mice, while sparing pigmentation in the eye and brain. Depig-
mentation in this model is correlated with melanocyte-speciﬁc
autoantibody production, and is dependent on CD4þ T cells rather
than CD8þ Tcells.59 An advantage of immunization-induced vitiligo
is the role of endogenous host immune cells in depigmentation,
which enables the investigation of host immune factors that
contribute to melanocyte destruction.DNA plasmids encoding human TRP2, a melanocyte antigen,
have been delivered directly into the skin of mice using a gene
gun.60,61 The DNA is ﬁrst coated on gold microparticles, which are
then delivered into the skin through a carbon dioxide-powered
gene gun. Tyrosinase-related protein 2 is then expressed in skin
cells transformed by the plasmid. After treatment, the regrowing
hairs are depigmented, which is dependent on CD8þ T cells and
their expression of perforin.60 Antibodies against human TRP2 have
also been induced.61 Studies that used gene gun-delivered plasmids
encoding human TRP-2 and human HSP70i increased depigmen-
tation in treated mice, whereas immunizations that lacked HSP70i
did not.20 This observation suggests that HSP70i contributes to
depigmentation. This connects HSP70i released by stressed mela-
nocytes to functional melanocyte-speciﬁc immune responses in
vitiligo. A follow-up study revealed that a mutated form of HSP70i
was unable to induce disease in this model, and prevented the in-
duction of the disease.62 This approach is well suited to study the
effects of adjuvants such as HSP70i in disease initiation and exac-
erbation because plasmids encoding key proteins can be simply
added during immunization.TCR transgenic hosts
The AADþ transgenicmouse expresses anMHC Imoleculewith the
peptide binding region of human HLA-A*021 and presents the
Figure 4 Mouse model of vitiligo with epidermal depigmentation. (A) Hosts for the adoptive transfer of T cells express stem cell factor (SCF) in keratinocytes, which retains
melanocytes in the epidermis and result in black skin and hair (a wild-type C57Bl6 mouse is on the left and a K14-SCF mouse is on the right). After the induction of vitiligo, patchy
epidermal depigmentation occurs in (B) the ears, (C) the feet, and (D) the tail; however, hair pigmentation is spared.
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that lacked the expression of tyrosinase. A T cell clone speciﬁc for
Tyr369 was isolated from these mice. The TCR genes from the clone
mice were used to generate TCR transgenic mice with CD8þ T cells
recognizing Tyr369 (i.e., FH mice). When FH mice were crossed to
AADþmice, spontaneous depigmentation occurred prominently in
the hair and weakly in the tail skin. Immunohistochemistry of the
affected skin and hair follicles revealed inﬁltrating CD8þ and CD4þ
T cells. This model is dependent on CD8þ T cells, whereas CD4þ T
cells are not required and negatively regulate disease. Depigmen-
tation depended on IFN-g and the chemokine receptors CXCR3 and
CCR5, which bind the IFN-g-induced chemokines CXCL9, CXCL10,
and CCL5.63
Mehrotra et al64 developed a transgenic mouse that develops
vitiligo by using mice that express a human melanocyte-speciﬁc
TCR and human HLA-A2. The human TCR used to create these
mice was cloned from a human CD4þ T cell inﬁltrating a melanoma
that had high afﬁnity for the tyrosinase368e376 peptide that pre-
sented on HLA-A2, which typically interacts with CD8þ T cells.
Depigmentation of the hairs in these mice occurs over time, and
histological examination reveals a loss of melanocytes in affected
hair follicles and antigen speciﬁc T cell inﬁltration of the skin.64
Because the T cells that are produced in these mice do not ex-
press CD4 or CD8, it is unclear whether their effector function is
more like CD4þ T cells (from which they are derived), or CD8þ T
cells (which normally interact with HLA-A2). Additional studies
may reveal how this interesting Tcell clone kills melanocytes in this
model.
The TrpHEL model results in hair depigmentation that is
mediated by CD4þ T cell recognition of a model antigen.
Membrane-bound hen egg lysozyme (HEL) was expressed in me-
lanocytes under the control of the TRP-2 promoter. These mice
were subsequently crossed to 3A9 CD4þ TCR mice, which have T
cells that recognize HEL peptide 46e61. The mice developed
depigmentation of their hair beginning at 21 days of age. The
mechanism of depigmentation was dependent on Fas-Fas ligand-
mediated melanocyte killing.65 However, human melanocytes
appear to be resistant to Fas-mediated killing,3 and therefore the
relevance of this model to human vitiligo is unclear.Induced through the adoptive transfer of TCR transgenic T cells
Muranski et al66 generated a transgenic mouse with a MHC II-
restricted (CD4þ) TCR recognizing TRP1. Adoptive transfer of
TRP1-specﬁic CD4þ T cells from these mice into a RAG1-deﬁcient or
sublethally irradiated C57Bl6 host resulted in rapid depigmentation
of the hair. Studies on human vitiligo skin and T cells ex vivo have
implicated CD8þ T cells in melanocyte destruction, but the role of
CD4þ T cells in human disease is unclear. This model provides an
opportunity to investigate potential CD4þ T cell contributions to
depigmentation in vitiligo. This is an area that requires more
insight.
Antony et al67 injected B16 melanoma cells into RAG-deﬁcient
hosts and then adoptively transferred activated CD8þ T cell clones
that recognize the melanocyte antigen gp100 (PMEL). The hosts
were also infected with fowlpox virus expressing the human gp100
peptide and either IL-2 or CD4þ T cells that had been depleted of T
regulatory cells. Tumors regressed in the hosts receiving these cells,
and hair depigmentation developed, which represent vitiligo
occurring after melanoma treatment. This model is dependent on
CD8þ T cell-mediated destruction of melanocytes and IFN-g,67 and
offers the ability to investigate depigmentation as a consequence of
melanoma-targeted immune responses.
Because human vitiligo is characterized by epidermal depig-
mentation and hairs are often spared within lesions, we developed
a mouse model of vitiligo with focused epidermal depigmentation
and sparing of the hairs. To do this, we adoptively transferred PMEL
CD8þ T cells into hosts that expressed stem cell factor in kerati-
nocytes, as described previously,68 and therefore retained mela-
nocytes in the epidermis. Thesemice have black skin and black hair.
To activate the T cells in vivo, the hosts were then sublethally
irradiated and treated with recombinant vaccinia virus expressing
the gp100 peptide. From 5 weeks to 7 weeks later, the mice
developed patches of depigmentation in the ears, tail, footpads, and
nose, with sparing of the hairs69 (Figure 4). The development of
prominent epidermal depigmentation is one strength of this
model, and allows investigation of mechanisms that direct T cell
migration through the skin to the epidermis. Using this model we
discovered that, similar to human disease, IFN-g induces CXCL9 and
Table 1 Summary of vitiligo models established in chickens and mice.a
Model Animal Mechanism Immune Stress Genetics Refs
Smyth Chicken Spontaneous T and B cells are required Increased ROS in
feathers
Inherited
depigmentation
45e51
Lerner Mouse Spontaneous N/A N/A Point mutation
in MITF
53
Zhu Mouse Application of MBEH to the
shaved abdomens of 4-week-old mice
CD8þ T cells inﬁltrate Stress required
to induce
depigmentation
N/A 58
Overwijk Mouse Immunization of B6 mice with
recombinant vaccinia virus expressing human TRP1
CD4þ T cells mediate the disease N/I N/A 59
Bowne Mouse Immunization with plasmids encoding human TRP2
on gold particles via gene gun
CD8þ T cells mediate the disease via a
perforin-dependent mechanism
N/I N/A 60
Gregg Mouse FH TCR transgenic mice expressing human
HLA-A*021 with CD8þ T cells recognizing Tyr369
CD8þ T cells mediate the disease and
inﬁltrate the skin; CD4þ inﬁltration is
also present but not required
N/I N/A 63
Mehrotra Mouse The TCR transgene expresses the complete
HLA-A2 molecule; TCRs recognize tyrosinase368-376
CD3þCD8CD4- T cells inﬁltrate the skin N/I N/A 64
Lambe Mouse CD4þ TCR transgene recognizes HEL, which is
expressed under the control of the TRP2 promoter
CD4þ T cells mediate the disease N/I N/A 65
Muranski Mouse TCR transgenic mouse with CD4þ T cells
that recognize TRP1
CD4þ T cells mediate the disease N/I N/A 66
Antony Mouse Injection of B16 melanoma cells, activated
PMEL T cells, virus encoding hgp100 peptide and IL-2
CD8þ T cells mediate the disease; IFN-g
is required
N/I N/A 67
Harris Mouse Adoptive transfer of TCR transgenic CD8þ T cells
recognizing melanocyte antigen PMEL into hosts
that retain melanocytes in the epidermis
CD8þ T cells mediate depigmentation in
an IFN-g dependent manner
N/I N/A 69
IFN-g ¼ interferon-gamma; MBEH ¼ monobenzyl ether of hydroquinone; MITF ¼ microphthalmia-associated transcription factor; N/A ¼ not applicable; N/I ¼ not investi-
gated; ROS ¼ reactive oxygen species; TCR ¼ T cell receptor; TRP1 ¼ tyrosinase-related protein 1; TRP2 ¼ tyrosinase-related protein 2.
a The models of vitiligo are listed with identiﬁed mechanistic contributions to disease, which include melanocyte stress, autoimmunity, and genetic factors.
K.I. Essien, J.E. Harris / Dermatologica Sinica 32 (2014) 240e247246CXCL10 in the skin and CXCR3 (their shared receptor) is expressed
on melanocyte-speciﬁc T cells. In this model, CXCL10 is required for
the progression and maintenance of vitiligo, which suggests that
targeting CXCL10 or its receptor CXCR3 may be a viable treatment
strategy.29 Because depigmentation in this model is epidermal, it
may be the better model to represent epidermal depigmentation in
human vitiligo because of the differences between epidermal and
follicular melanocytes, as previously described. This model is also
well suited to study topical agents that modify disease severity,
including immune modulators to treat disease and stress-inducing
agents to investigate chemical-induced vitiligo.
A similar model described by Antony et al67 exhibits hair
involvement; however, our model maintains the immune privilege
of the hair, thereby providing an opportunity to study the factors
that contribute to the immune privilege of the hair follicle. The
difference in hair involvement between themodels may be because
their model uses RAG-deﬁcient host mice, which lack T regulatory
cells (Tregs), and Tregs have been reported in other mouse models
to limit disease severity.63,70Conclusion
Vitiligo has a complex, multifactorial pathogenesis. Studies con-
ducted directly in humans and their tissues are important, but are
primarily limited to correlative observations. Combining mecha-
nistic studies in animal models with observational studies in
humans and their tissues is a powerful approach to better under-
stand vitiligo pathogenesis and to develop new treatments for the
disease. However, fewmodels reﬂect the entire spectrum of human
disease pathogenesis, and therefore the availability of multiple
systems provides complimentary tools for this purpose (Table 1).
Spontaneous models of vitiligo provide an opportunity to investi-
gate how vitiligo is initiated, and the genetic contributions to dis-
ease. The SL chicken appears to exhibit multiple characteristics of
vitiligo that parallel human disease. Future studies in this model
may help to clarify interactions between melanocyte stress and
autoimmunity that drive depigmentation. Induced models ofvitiligo have been primarily conducted in mice, which are less
expensive to breed and maintain, and provide a large number of
tools to study mechanistic contributions to vitiligo pathogenesis.
These models are well suited to study mechanisms that drive dis-
ease progression, which are particularly relevant to therapeutic
intervention. In summary, animal models provide an opportunity
for mechanistic studies to deﬁne vitiligo pathogenesis. Each model
has its strengths and weaknesses, and should be selected based on
the experimental questions being addressed.References
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